Inflammatory bowel disease in patients undergoing renal biopsies

Jussi Pohjonen\textsuperscript{1,2}, Rakel Nurmi\textsuperscript{1}, Martti Metso\textsuperscript{2}, Pia Oksanen\textsuperscript{3,4}, Heini Huhtala\textsuperscript{5}, Ilkka Pörsti\textsuperscript{2,4}, Jukka Mustonen\textsuperscript{2,4}, Katri Kaukinen\textsuperscript{1,2} and Satu Mäkelä\textsuperscript{2,4}

\textsuperscript{1}Celiac Disease Research Center, Faculty of Medicine and Life Sciences, Tampere University, Tampere, Finland, \textsuperscript{2}Department of Internal Medicine, Tampere University Hospital, Tampere, Finland, \textsuperscript{3}Department of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital, Tampere, Finland, \textsuperscript{4}Faculty of Medicine and Life Sciences, Tampere University, Tampere, Finland and \textsuperscript{5}Faculty of Social Sciences, Tampere University, Tampere, Finland

Correspondence and offprint requests to: Jussi Pohjonen; E-mail: jussi.pohjonen@tuni.fi

ABSTRACT

Background. There are no good data in the literature on the prevalence of inflammatory bowel disease (IBD) in patients with kidney disease and we do not know whether IBD affects the course of kidney disease or if the type of IBD is an influential factor. The aim of this study was to evaluate the prevalence of IBD among patients who have undergone renal biopsies due to clinical indications and to elucidate whether the presence of IBD influences renal and patient outcomes.

Methods. We collected retrospective data on concomitant diseases, especially IBD, from adult patients undergoing renal biopsy for any clinical indication between 2000 and 2012 at Tampere University Hospital, Tampere, Finland. Information was systematically collected on the activity of IBD, medication for IBD, surgery performed for IBD and markers of kidney function.

Results. Of the 819 patients biopsied, 35 (4.3%) had IBD. The prevalence of IBD was 13.3 and 4.6% in patients with tubulointerstitial nephritis (TIN) and immunoglobulin A nephropathy (IgAN), respectively. In comparison, the prevalence of IBD in the Finnish population is 0.6%. Ulcerative colitis and Crohn's disease were equally represented. The presence of IBD showed no impact on renal and patient outcomes.

Conclusions. IBD should not be overlooked in patients undergoing renal biopsies, especially those diagnosed with TIN or IgAN. The renal findings did not associate with the activity of intestinal inflammation. Whether a concomitant IBD truly affects the course of chronic kidney disease should be examined in further studies.

Keywords: chronic kidney failure, IgA glomerulonephritis, inflammatory bowel diseases, Interstitial nephritis, renal biopsy
INTRODUCTION

Many publications have raised our awareness of the relationship between kidney diseases and increased intestinal permeability. Chronic kidney disease (CKD), and especially uraemia, alters the intestinal barrier and microbiome. The loss of the ability to prevent the influx of microbial toxins and other harmful products leads to local and systemic inflammation, which can further promote deterioration in kidney function [1–3]. This phenomenon probably promotes cardiovascular diseases as well, which are one of the leading causes of death in patients with end-stage renal disease (ESRD) [4]. Interestingly, intestinal permeability seems to be already increased in the earlier stages of CKD [5]. The linkage between the most common primary glomerulopathy [6], immunoglobulin A nephropathy (IgAN) and the mucosa is well known [7, 8]. Genome-wide association studies (GWASs) in patients with IgAN have identified risk loci in the immune network [9]. In one recent study, patients with IgAN who had persistent proteinuria were treated with targeted-release enteric budesonide, which resulted in a significant reduction in proteinuria [10].

Inflammatory bowel diseases (IBDs), including ulcerative colitis (UC) and Crohn’s disease (CD), are increasingly common chronic inflammatory disorders of the gastrointestinal tract: the prevalence of IBD is currently 0.2–0.7% in Western countries [11–14]. Inflammation affects the large intestine and rectum in UC [15], whereas inflammation and progressive bowel damage can be present in any part of the intestine in CD [16]. A third entity is unclassified IBD (IBDU), in which inflammation of the intestine with chronic colitis is present but no characteristic histological signs of UC or CD are found [11]. IBD requires lifelong management. Renal damage in patients using 5-aminosalicylic acid (5-ASA) medication is a rare but well-documented phenomenon probably promotes cardiovascular diseases as well. The loss of the ability to prevent the influx of microbial toxins and other harmful products leads to local and systemic inflammation, which can further promote deterioration in kidney function [1–3]. This phenomenon probably promotes cardiovascular diseases as well, which are one of the leading causes of death in patients with end-stage renal disease (ESRD) [4]. Interestingly, intestinal permeability seems to be already increased in the earlier stages of CKD [5]. The linkage between the most common primary glomerulopathy [6], immunoglobulin A nephropathy (IgAN) and the mucosa is well known [7, 8]. Genome-wide association studies (GWASs) in patients with IgAN have identified risk loci in the immune network [9]. In one recent study, patients with IgAN who had persistent proteinuria were treated with targeted-release enteric budesonide, which resulted in a significant reduction in proteinuria [10].

Inflammatory bowel diseases (IBDs), including ulcerative colitis (UC) and Crohn’s disease (CD), are increasingly common chronic inflammatory disorders of the gastrointestinal tract: the prevalence of IBD is currently 0.2–0.7% in Western countries [11–14]. Inflammation affects the large intestine and rectum in UC [15], whereas inflammation and progressive bowel damage can be present in any part of the intestine in CD [16]. A third entity is unclassified IBD (IBDU), in which inflammation of the intestine with chronic colitis is present but no characteristic histological signs of UC or CD are found [11]. IBD requires lifelong management. Renal damage in patients using 5-aminosalicylic acid (5-ASA) medication is a rare but well-documented phenomenon probably promotes cardiovascular diseases as well. The loss of the ability to prevent the influx of microbial toxins and other harmful products leads to local and systemic inflammation, which can further promote deterioration in kidney function [1–3]. This phenomenon probably promotes cardiovascular diseases as well, which are one of the leading causes of death in patients with end-stage renal disease (ESRD) [4]. Interestingly, intestinal permeability seems to be already increased in the earlier stages of CKD [5]. The linkage between the most common primary glomerulopathy [6], immunoglobulin A nephropathy (IgAN) and the mucosa is well known [7, 8]. Genome-wide association studies (GWASs) in patients with IgAN have identified risk loci in the immune network [9]. In one recent study, patients with IgAN who had persistent proteinuria were treated with targeted-release enteric budesonide, which resulted in a significant reduction in proteinuria [10].

MATERIALS AND METHODS

Patients and study design

The study cohort comprised 824 consecutive patients >16 years of age who had undergone a renal biopsy due to clinical indications at the Division of Nephrology at Tampere University Hospital (TAUH), Tampere, Finland, between January 2000 and December 2012. The data were missing in five patients, giving the study population of 819 patients. All patients included in the study provided written informed consent. If the same patient was biopsied twice during the study period, then the first diagnostic biopsy was included in the study. Renal biopsy specimens were taken and processed using standard methods as described earlier [29]. All specimens were studied with light and immunofluorescence microscopy by two renal pathologists.

The indications for renal biopsies were classified into three groups: (i) abnormal urinary finding, including focal nephritic syndrome (haematuria and daily urinary protein excretion <1.5 g), diffuse nephritic syndrome (haematuria and daily urinary protein excretion >1.5 g), nephrotic syndrome (daily urinary protein excretion >3.5 g without haematuria), proteinuria (daily urinary protein excretion 0.3–3.5 g without haematuria) and haematuria (daily urinary protein excretion <0.3 g); (ii) renal insufficiency (elevated creatinine level) and (iii) any other indication. Based on the histopathological findings of the renal biopsy specimens, five groups were categorized: glomerular diseases, tubulointerstitial diseases, vascular diseases, other findings (e.g. cystic and congenital diseases) and no glomeruli (inadequate sample) [30]. Patients were divided into two groups based on whether they were diagnosed with IBD or not.

Clinical data on kidney disease

The histories of all 819 patients were retrospectively collected from the medical records of TAUH between 2014 and 2016 [8]. Plasma creatinine concentration, quantitative 24-h urinary protein excretion and haematuria data were gathered from medical records at the time of the renal biopsy and the most recent follow-up. The urine dipstick test for haematuria was dichotomized as negative (values 0 or +) or positive (+ or ++). Estimated glomerular filtration rate (eGFR) was defined using the Chronic Kidney Disease Epidemiology Collaboration equation [30]. The annual change in eGFR was calculated by dividing the difference between the final and baseline values of eGFR by the number of years of follow-up. Only patients followed up for >1 year after the renal biopsy with preserved kidney function (no transplantation or chronic dialysis started during follow-up) were included in the calculations of kidney function at the most recent follow-up. Furthermore, data on chronic dialysis treatment or renal transplantation during follow-up were recorded and collectively called ESRD. The follow-up for individual patients was concluded at the last office visit or the last reliable set of laboratory results, whichever was closer to the time of data collection.

Clinical data on IBD

Information regarding other diagnosed diseases, including IBD, was collected systematically. The EIMs comprised diseases of organs commonly accepted to be involved in IBD—diseases of the joints, eyes, skin, liver, biliary tract and urinary tract—as well as thrombotic events. Detailed data on IBD activity, medication, location, surgery and EIMs were collected. The immunomodulatory medications for IBD included azathioprine, methotrexate, glucocorticoids or tumour necrosis factor (TNF) inhibitors. IBD flare-up was defined as the need for systemic glucocorticoid medication equivalent to ≥30 mg of prednisolone. The site of IBD was determined by means of endoscopy or gastrointestinal imaging (e.g. enteric magnetic resonance imaging) reports and grouped into five different categories as follows: proctitis, left-sided colitis (including proctosigmoiditis), pancolitis/ileocolonic, small intestinal (no colonic affliction) and unknown. Abdominal surgery denoted any surgical procedure to the intestine (including appendectomy); operations on abdominal fistulas, strictures, hernias or abscesses and cholecystectomy.

Statistical methods

The data are presented as medians and ranges for continuous variables and numbers and percentages for categorical
variables. Groups were compared using the chi-square test, Fisher's exact test, independent t-test or Mann–Whitney U-test, as appropriate. Survival (ESRD as event) was determined using Kaplan–Meier curves and differences between IBD (yes/no) were compared by log-rank test. Univariate and multivariable analyses (adjusted for age, gender and presence of IBD) were performed using Cox proportional hazards regression. Hazard ratios and their 95% confidence intervals are given. All tests were two-sided and P < 0.05 was considered statistically significant. All statistical testing was performed using SPSS version 25.0 (IBM, Armonk, NY, USA).

Ethical consideration
The study protocol was approved by the Ethics Committee of Tampere University Hospital. All subjects gave written informed consent at the time of the renal biopsy.

RESULTS
Patient characteristics, renal biopsy findings and the prevalence of IBD

Twenty-eight (3.4%) of 819 patients had IBD at the time of renal biopsy and an additional 7 patients were diagnosed with IBD during the follow-up. Therefore a total of 35 (4.3%) patients had IBD (Table 1). The patients with IBD were younger than the patients without IBD. There were no differences in indications for renal biopsy between the patients with and without IBD (Table 1).

The most common renal biopsy finding in the patients with IBD was acute (four patients) or chronic (four patients) tubulointerstitial nephritis (TIN). Altogether, 22.9% of the patients with IBD presented with TIN, while 7 patients (20.0%) had IgAN. Ten patients had glomerular diseases other than IgAN, two patients had tubulointerstitial diseases other than TIN and eight patients had findings categorized as vascular diseases or other renal findings (Table 2). Tubulointerstitial diseases were more often found in the patients with IBD when compared with patients without IBD (28.6 versus 12.5%; P = 0.017) and glomerular diseases dominated in the patients without IBD when compared with patients with IBD (70.9 versus 48.6%; P = 0.007). Among the patients without IBD, TIN was diagnosed in 6.7% and IgAN in 18.4% of patients. Overall, the prevalence of IBD in the patients with TIN was 13.3%. Seven of 151 patients (4.6%) with IgAN had IBD compared with 8 of 308 patients (2.6%) with a glomerular disease other than IgAN (P = 0.164).

Patients with IBD and TIN were almost exclusively women (seven of eight patients), while no sex difference was found in patients with TIN and with no IBD (female 50.0%). Patients with a glomerular disease (including IgAN) and IBD were predominantly male [14/17 patients (82.4%)]. A preponderance of males was also found in patients with glomerular disease and no IBD [344/556 patients (61.9%)].
Renal outcomes

The median follow-up time was 59 months in patients with IBD and 66 months in patients without IBD. There was no difference between the groups in eGFR at the time of renal biopsy or at the most recent follow-up. Patients with IBD had significantly lesser amounts of proteinuria at the time of renal biopsy (Table 3). The 24-h urinary protein excretion was quantitated in 26 of 35 patients with IBD. Of these, nine (34.6%) were using immunomodulatory medication at the time of renal biopsy. Yet the amount of proteinuria did not differ between those who were on immunomodulatory medication and those who were not (median of the 24-h excretion 0.8 and 0.9 g, respectively; \( P = 0.833 \)). Two patients with IBD (5.7%) and 142 patients without IBD (18.1%) progressed to ESRD (\( P = 0.068 \)). In Figure 1, a Kaplan–Meier curve shows the difference between patients with and without IBD and the occurrence of ESRD. We also performed Cox logistic regression analysis to determine the risk factors for ESRD (Table 4). Male gender was found to be a strong and independent predictor of ESRD, but the presence of IBD did not associate with the risk for ESRD.

Phenotypes of IBD

Altogether, there were 14 cases of CD, 14 cases of UC and 7 cases of IBDU. Neither CD nor UC seemed to dominate in the different renal findings for TIN (three CD, four UC and one IBDU), IgAN (four CD and three UC) or other GD (four CD, four UC and two IBDU). All patients with TIN had a previous diagnosis of IBD and all of them used or had prior use of 5-ASA medication at the time of renal biopsy. Similarly, patients with glomerular diseases who had a diagnosis of IBD at the time of renal biopsy (13 patients) all had a history of 5-ASA medication. Altogether, 37.1% of the patients with IBD were taking either steroid or other immunomodulatory medication (azathioprine, methotrexate or TNF inhibitor) at the time of the renal biopsy. In terms of inflammatory activity, one-quarter (7/28) of the patients with previous IBD had a flare-up of IBD during the year preceding the renal biopsy.

Diffuse intestinal inflammation (pancolitis or ileocolonic) was the most common (54.2%) location of IBD, irrespective of the renal finding. Nine of 35 (25.7%) patients had undergone abdominal surgery. Most of the patients with IgAN and IBD had an EIM (71.4%), while just 12.5% of the patients with TIN and 20.0% of the patients with other glomerular diseases had an EIM.

DISCUSSION

This study showed the prevalence of IBD among people undergoing renal biopsy to be as high as 3.4%; during the follow-up, the prevalence of diagnosed IBD was further elevated to 4.3%. As the pathogenesis of diseases can presumably take a variable number of years before clinical symptoms arise and the spectrum of symptoms of both renal diseases and IBD is wide, a clear determination cannot be made as to whether renal disease or IBD preceded the other in individual patients.

The prevalence of IBD in our study was large compared with that found (0.2%) in a previous study by Ambruzs et al. [27]. The major difference in the prevalence of IBD in these two studies is most likely explained by differences in study designs. Between 1986 and 2008, the prevalence of IBD has increased from 0.2 to 0.6% in Finland [11, 12]. There are few published prevalence.

Table 3. Renal function at the time of renal biopsy and at the latest follow-up

|                      | Patients with IBD (n = 35), median (range) | Patients without IBD (n = 784), median (range) | P-value |
|----------------------|-------------------------------------------|------------------------------------------------|---------|
| At renal biopsy      |                                           |                                                 |         |
| Plasma creatinine (μmol/L) | 133 (56–671)                                | 123 (17–1776)                                 | 0.921   |
| eGFR (mL/min/1.73 m²) | 44 (6–130)                                  | 51 (2–172)                                    | 0.711   |
| 24-h urinary protein excretion (g/day) | 0.8 (0.1–6.4)                | 1.5 (0.1–24.2)                                 | 0.040   |
| Haematuria, n (%)    | 12 (37.5)                                   | 346 (46.9)                                    | 0.366   |
| At the latest follow-up |                                         |                                                 |         |
| Duration of follow-up (months) | 59 (0–178)                                | 66 (0–183)                                    | 0.619   |
| Plasma creatinine (μmol/L) | 90 (49–276)                                | 104 (11–1013)                                 | 0.137   |
| eGFR (mL/min/1.73 m²)  | 78 (19–117)                                 | 57 (4–197)                                    | 0.118   |
| Annual change of eGFR (mL/min/1.73 m²/year) | 0 (–11–35)                       | –1 (–84–70)                                   | 0.086   |

\( ^{a} \text{eGFR was calculated by the Chronic Kidney Disease Epidemiology Collaboration equation. Number of subjects available:} \)

\( ^{b} 621; \)

\( ^{c} 769; \)

\( ^{d} \text{excluded if treated with dialysis, had received renal transplantation during the follow-up or the follow-up had lasted <12 months;} \)

\( ^{e} 567; \)

\( ^{f} 552. \)
rates of IBD globally, but they seem to vary from 0.2 to 0.7% [11, 13, 14]. Thus the prevalence of IBD in the present cohort of patients who had a clinical indication for the renal biopsy was approximately 7-fold compared with that in the general population.

The prevalences of IBD in patients with TIN and IgAN were as high as 13.3 and 4.6%, respectively. This is about 20- and 8-fold the IBD prevalence in the general population, respectively. In previous studies, the prevalence of IBD in IgAN patients has varied from 0.7 to 1.6% [27, 31, 32]. To our knowledge, the prevalence of IBD in patients with TIN has not been published before. There is no way to differentiate patients in this cohort for whom TIN was related to 5-ASA medication, as all the patients with TIN had an ongoing or previous history of 5-ASA use. Thus the high prevalence of IBD in patients with TIN might have been related to 5-ASA medication even though the correlation of 5-ASA to TIN has remained controversial in the literature [38–40]. In general, patients without IBD had greater amounts of proteinuria at the time of renal biopsy, a finding that most likely is explained by the dominance of glomerular diseases in patients without IBD. The preponderance of the female gender in patients with TIN and IBD was noteworthy, but the small number of patients with both IBD and TIN might have influenced the results. The finding of a male majority in patients with glomerulonephritis (GN) in general has been noted in earlier publications [34, 35] and recently in patients with IBD and GN as well [28]. Patient cases of TIN and IBD have not shown female dominance [33, 36, 37].

The connection between IgAN and intestinal inflammation is clearly recognized [7]. The HLA-DR1 allele for IgAN and the HLA-DR1/DQw5 allele for CD have led to a theory of a common genetic basis for both diseases [24]. GWASs in patients with IgAN have identified risk loci in genes involved in intestinal mucosal integrity and the immune network. Some of the risk alleles for IgAN are also associated with the risk for IBD [9]. The number of inflammatory cells in the intestinal mucosa increased in patients with GN [38–40]. However, no previous publication has shown such a high prevalence of IBD in patients with IgAN.

Previously, more than half of the patients with IgAN have presented with various other parallel diseases [31, 32]. No published data exist on the incidence of IBD and IgAN in association with a third disease entity, but patient cases of such triads have been published [41–43], as has one recent case series [28]. In our cohort, 71% of patients with IBD and IgAN had another EIM.

Male gender presented as a risk factor for ESRD. This finding is in line with previous publications [44, 45]. IBD was not related to an elevated risk for ESRD. The impression that the activity of IBD affects renal disease can arise when reading published patient cases [46–48]. Defining the activity of the disease in a retrospective manner is rather inaccurate. We can assume, based on the data shown, that the patients in the present study did not represent particularly difficult cases of colitis. Fewer than half of the patients with a previous diagnosis of IBD either had a flare-up during the preceding year before the kidney biopsy or were on an immunomodulatory medication at the time of the renal biopsy. Nevertheless, more than half had no clinical sign of active intestinal inflammation, and when the total population of 35 patients with IBD was evaluated, about one-third of the patients with IBD had intestinal inflammatory activity at the time of the renal biopsy. A quarter of the patients with IBD had undergone abdominal surgery at any given time point, either before or after the kidney biopsy. No clear difference was noticed in the concomitance of renal disease and IBD, as CD and UC were equally represented. In a recent letter published by Hungarian researchers, the few cases of GN found in patients with IBD were more often in conjunction with CD [28].

The renal biopsies in this study were taken at one centre and analysed by two renal pathologists. The unifying indications for renal biopsies as well as the interpretation of the renal samples are the strengths in the present study. Patients with renal diseases in our university hospital district are mostly followed up and treated in the nephrology unit of the university hospital. In a similar way, most of the patients with active IBD are followed up by the university hospital. Thus we have been able to collect real-life data with long follow-up times. Due to the retrospective nature of the study, some of the information collected may be inaccurate or insufficient. Another obvious limitation is that some of the patients with no diagnosed IBD might have had clinically silent IBD, but the number of such patients presumably would be low and would not affect the results of the study.

To conclude, our study showed a remarkable prevalence of IBD in patients undergoing renal biopsy for any clinical indication. IBD should be kept in mind when the renal biopsy finding is either TIN or IgAN. A lack of obvious gastrointestinal symptoms does not necessarily indicate the absence of IBD, as more than half of the patients biopsied were asymptomatic at the time of biopsy. We do not yet know whether the coexistence of IBD and CKD results in one influencing the other. This cohort was too small to show either the benefit or disadvantage of IBD for CKD even though patients with IBD did well when compared with patients without IBD. Thus further studies are needed to examine the significance of concomitant IBD in patients with CKD.

ACKNOWLEDGEMENTS

The authors are very grateful to Raija Hukkila and Marja-Leena Koskinen for their excellent technical assistance. The valuable work of Docent Ole Wirta (MD, PhD) is greatly appreciated.

FUNDING

This study was supported by the Academy of Finland, the Competitive State Research Financing of the Expert Responsibility Area of Tampere University Hospital (9U019, 9T018, 9S020, 9S059) and the Sigrid Juselius Foundation. The funding sources had no involvement in the study design, in the collection, analysis and interpretation of the data; in the writing of the report or in the decision to submit the article for publication.

AUTHORS’ CONTRIBUTIONS

All authors participated in the design of the study. J.P., R.N. and M.M. collected the data. J.P. and H.H. analysed and
interpreted the data. J.P. drafted the article. All authors read, revised and approved the final manuscript.

CONFLICT OF INTEREST STATEMENT

The authors had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. The manuscript contents have not been copyrighted or previously published, except in abstract form for the Annual Medical Congress arranged by the Finnish Medical Society Duodecim and the Medical Society of Tampere, Finland. We have no conflicts of interest to declare.

REFERENCES

1. Vaziri ND, Wong J, Pahl M. Chronic kidney disease alters intestinal microbial flora. Kidney Int 2013; 83: 308–315
2. Vaziri ND, Yuan J, Nazertehrani S et al. Chronic kidney disease causes disruption of gastric and small intestinal epithelial tight junction. Am J Nephrol 2013; 39: 99–103
3. Vaziri ND, Zhao Y, Pahl MV. Altered intestinal microbial flora and impaired epithelial barrier structure and function in CKD: the nature, mechanisms, consequences and potential treatment. Nephrol Dial Transplant 2016; 31: 737–746
4. Anders H, Andersen K, Stecher B. The intestinal microbiota, a leaky gut, and abnormal immunity in kidney disease. Kidney Int 2013; 83: 1010–1016
5. Rostoker G, Wirquin V, Terzidis H et al. Mucosal immunity in primary glomerulonephritis. III. Study of intestinal permeability. Nephron 1993; 63: 286–290
6. Geddes CC, Rauta V, Gronhagen-Riska C et al. A tricontinental view of IgA nephropathy. Nephrol Dial Transplant 2003; 18: 1541–1548
7. Coppo R. The intestine-renal connection in IgA nephropathy. Nephrol Dial Transplant 2015; 30: 360–366
8. Nurmi R, Metso M, Pörsti I et al. Celiac disease or positive tissue transglutaminase antibodies in patients undergoing renal biopsies. Dig Liver Dis 2018; 50: 27–31
9. Kyrulk K, Li Y, Scolari F et al. Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet 2014; 46: 1187–1196
10. Fellström BC, Barratt J, Cook H et al. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. Lancet 2017; 389: 2117–2127
11. Manninen P, Karvonen A, Huhtala H et al. The epidemiology of inflammatory bowel diseases in Finland. Scand J Gastroenterol 2010; 45: 1063–1067
12. Jussila A, Virta LJ, Salomaa V et al. High and increasing prevalence of inflammatory bowel disease in Finland with a clear North-South difference. J Crohns Colitis 2013; 7: e262
13. Hein R, Köster I, Bolischweier E et al. Prevalence of inflammatory bowel disease: estimates for 2010 and trends in Germany from a large insurance-based regional cohort. Scand J Gastroenterol 2014; 49: 1325–1335
14. Herrinton LJ, Liu L, Lafata JE et al. Estimation of the period prevalence of inflammatory bowel disease among nine health plans using computerized diagnoses and outpatient pharmacy dispensings. Inflamm Bowel Dis 2007; 13: 451–461
15. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010; 105: 501–523
16. Danese S, Fiorino G, Peyrin-Biroulet L. Early intervention in Crohn’s disease: towards disease modification trials. Gut 2017; 66: 2179–2187
17. Ransford Raj, Langman MJS. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut 2002; 51: 536–539
18. Gisbert JP, González-Lama Y, Mate J. S-aminosalicylates and renal function in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis 2007; 13: 629–638
19. Patel H, Barr A, Jeejeebhoy KN. Renal effects of long-term treatment with S-aminosalicylic acid. Can J Gastroenterol 2009; 23: 170–176
20. Van Staa TP, Travis S, Leufkens HGM et al. S-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study. Gastroenterology 2004; 126: 1733–1739
21. Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel disease. World J Gastroenterol 2006; 12: 4819–4831
22. Danese S, Semeraro S, Papa A. Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol 2005; 11: 7227–7236
23. Pardi DS, Tremaine WJ, Sandborn WJ et al. Renal and urologic complications of inflammatory bowel disease. Am J Gastroenterol 1998; 93: 504–514
24. Oikonomou K, Kapsoritakis A, Eleftheriadis T et al. Renal manifestations and complications of inflammatory bowel disease. Inflamm Bowel Dis 2011; 17: 1034–1045
25. Filiopoulos V, Trompouki S, Hadjiyannakos D et al. IgA nephropathy in association with Crohn’s disease: a case report and brief review of the literature. Ren Fail 2010; 32: 523–527
26. Shaer AJ, Stewart LR, Cheek DE et al. IgA antiglomerular basement membrane nephritis associated with Crohn’s disease: a case report and review of glomerulonephritis in inflammatory bowel disease. Am J Kidney Dis 2003; 41: 1097–1109
27. Ambruž J, Walker PD, Larsen CP. The histopathologic spectrum of kidney biopsies in patients with inflammatory bowel disease. Clin J Am Soc Nephrol 2014; 9: 265–270
28. Vech Z, Mcsail E, Lakatos L et al. The incidence of glomerulonephritis in a population-based inception cohort of patients with inflammatory bowel disease. Dig Liver Dis 2017; 49: 718–719
29. Wirta O, Mustonen J, Helin H et al. Incidence of biopsy-proven glomerulonephritis. Nephrol Dial Transplant 2008; 23: 193–200
30. Kidney Disease: Improving Global Outcomes CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013; 3: 1–150
31. Makdass R, Beaufils M, Meyrier A et al. Pathologic conditions associated with IgA mesangial nephropathy: preliminary results. Contrib Nephrol 1984; 40: 292–295
32. Mustonen J, Pasternack A. Associated diseases in IgA nephropathy. In: Clarkson AR (ed). IgA Nephropathy. Topics in Contrib Nephrol, Vol. 2. Boston: Springer, 1987, 47–65
33. Izzi-dine H, Simon J, Piette A-M et al. Primary chronic interstitial nephritis in Crohn’s disease. Gastroenterology 2002; 123: 1436–1440
34. Wilcox GM, Aretz HT, Roy MA et al. Glomerulonephritis associated with inflammatory bowel disease. Report of a patient
with chronic ulcerative colitis, sclerosing cholangitis, and acute glomerulonephritis. Gastroenterology 1990; 98: 786–791
35. Presti ME, Neuschwander-Tetri BA, Vogler CA et al. Sclerosing cholangitis, inflammatory bowel disease, and glomerulonephritis: a case report of a rare triad. Dig Dis Sci 1997; 42: 813–816
36. Thuluvath PJ, Ninkovic M, Calam J et al. Mesalazine induced interstitial nephritis. Gut 1994; 35: 1493–1496
37. Vuotila M, Ikaheimo R, Pietilainen T. Interstitial nephritis associated with mesalazine therapy. Duodecim 2003; 119: 1978–1982
38. Rantala I, Collin P, Holm K et al. Small bowel T cells, HLA class II antigen DR, and GroEL stress protein in IgA nephropathy. Kidney Int 1999; 55: 2274–2280
39. Honkanen T, Mustonen J, Kainulainen H et al. Small bowel cyclooxygenase 2 (COX-2) expression in patients with IgA nephropathy. Kidney Int 2005; 67: 2187–2195
40. Rostoker G, Delchier JC, Chaumette MT. Increased intestinal intra-epithelial T lymphocytes in primary glomerulonephritis: a role of oral tolerance breakdown in the pathophysiology of human primary glomerulonephritides? Nephrol Dial Transplant 2001; 16: 513–517
41. Peeters AJ, van den Wall Bake AW, Daha MR et al. Inflammatory bowel disease and ankylosing spondylitis associated with cutaneous vasculitis, glomerulonephritis, and circulating IgA immune complexes. Ann Rheum Dis 1990; 49: 638–640
42. de Moura CG, de Moura TC, de Souza SP et al. Inflammatory bowel disease, ankylosing spondylitis, and IgA nephropathy. J Clin Rheumatol 2006; 12: 106–107
43. Ku E, Ananthapanyasut W, Campese VM. IgA nephropathy in a patient with ulcerative colitis, Graves disease and positive myeloperoxidase ANCA. Clin Nephrol 2012; 77: 146–150
44. Kastarin M, Juutilainen A, Kastarin H et al. Risk factors for end-stage renal disease in a community-based population: 26-year follow-up of 25, 821 men and women in eastern Finland. J Intern Med 2010; 267: 612–620
45. Hsu C, Iribarren C, McCulloch CE et al. Risk factors for end-stage renal disease: 25-year follow-up. Arch Intern Med 2009; 169: 342–350
46. Forshaw MJ, Guirguis O, Hennigan TW. IgA nephropathy in association with Crohn’s disease. Int J Colorectal Dis 2005; 20: 463–465
47. Choi J-Y, Yu CH, Jung H-Y et al. A case of rapidly progressive IgA nephropathy in a patient with exacerbation of Crohn’s disease. BMC Nephrol 2012; 13: 84
48. Onime A, Agaba EI, Sun Y et al. Immunoglobulin A nephropathy complicating ulcerative colitis. Int Urol Nephrol 2006; 38: 349–353